Pneumonia Therapeutics Market Analysis: Growth, Size, Share & Future Trends (2024-2029)
The market report offers a detailed analysis segmented by Therapeutics (Prevention Vaccines, Treatment Drugs); by Distribution Channel (Hospital, Pharmaceutical Stores, Others); by Age Group (Pediatric, Adult, Geriatric); by Geography (North America, South America, Asia Pacific, Europe, The Middle East, Africa).
Outlook
- The pneumonia therapeutics market is estimated to be at USD 16,980.24 Mn in 2024 and is anticipated to reach USD 24,980.12 Mn in 2029.
- The pneumonia therapeutics market is registering a CAGR of 8.03% during the forecast period of 2024-2029.
- The pneumonia therapeutics market is driven by rising incidences of pneumonia, particularly among vulnerable populations such as the elderly and individuals with chronic diseases. Increasing healthcare awareness, improved diagnostics, and growing vaccine adoption are contributing to market expansion.
Request a free sample.
Ecosystem
- The participants in the global pneumonia therapeutics industry are always developing their strategies to preserve a competitive advantage.
- Smaller biotech firms like Moderna and BioNTech are introducing novel mRNA-based therapies for respiratory infections, driven by recent advances in vaccine technology seen during the COVID-19 pandemic.
- Several important entities in the pneumonia therapeutics market include GSK Plc.; Lupin Ltd.; Bayer AG; Teva Pharmaceutical Industries Ltd.; Abbott Laboratories; and others.
Ask for customization.
Findings
| Attributes | Values |
|---|---|
| Historical Period | 2018-2022 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Market Size (2024) | USD 16,980.24 Mn |
| Market Size (2029) | USD 24,980.12 Mn |
| Growth Rate | 8.03% CAGR from 2024 to 2029 |
| Key Segments | Therapeutics (Prevention Vaccines, Treatment Drugs); Distribution Channel (Hospital, Pharmaceutical Stores, Others); Age Group (Pediatric, Adult, Geriatric); Geography (North America, South America, Asia Pacific, Europe, The Middle East, Africa) |
| Key Vendors | GSK Plc.; Lupin Ltd.; Bayer AG; Teva Pharmaceutical Industries Ltd.; Abbott Laboratories |
| Key Countries | The US; Canada; Mexico; Brazil; Argentina; Colombia; Chile; China; India; Japan; South Korea; The UK; Germany; Italy; France; Spain; Turkey; UAE; Saudi Arabia; Egypt; South Africa |
| Largest Market | Asia Pacific |
Get a free quote.
Trends
- Advancements in Personalized Medicine: Tailoring pneumonia treatments based on genetic and biomarker profiles is becoming viable. Roche is exploring personalized approaches that target specific strains of pneumonia, enhancing treatment efficacy and reducing side effects.
- Monoclonal Antibodies: The development of monoclonal antibody therapies is gaining momentum, offering an alternative to traditional antibiotics, especially in cases of drug-resistant pneumonia. These therapies are showing promise in clinical trials for reducing infection severity and improving recovery rates.
- Growing Role of AI in Drug Discovery: Artificial intelligence is being leveraged to speed up the identification of new pneumonia treatments. For Instance, BenevolentAI is using AI to discover novel compounds that could be effective against pneumonia, providing a technological edge in drug development.
Speak to analyst.
Catalysts
- Government Initiatives and Funding: Increased government funding and initiatives to combat pneumonia are creating opportunities for market players. The Bill & Melinda Gates Foundation has funded several projects aimed at developing low-cost pneumonia treatments, incentivizing innovation in the sector.
- Rise in Antibiotic Resistance: The increasing resistance to traditional antibiotics is driving research for new treatments. For instance, GSK’s antibiotic Zavicefta is used to treat drug-resistant pneumonia, addressing the growing need for effective therapies.
- Prevalence of Chronic Diseases: Rising rates of chronic conditions like diabetes and COPD heighten the risk of pneumonia, driving market growth. In developed nations, these comorbidities contribute to a higher incidence of pneumonia, necessitating ongoing therapeutic development.
Inquire before buying.
Restraints
- High Cost of Advanced Therapies: Newer, more effective treatments such as monoclonal antibodies are expensive. In low-income regions, patients often can’t afford these life-saving medications.
- Limited Access to Healthcare: Rural and underserved populations often lack access to timely diagnosis and treatment. For example, pneumonia mortality is higher in remote parts of sub-Saharan Africa due to healthcare inaccessibility.
- Variable Vaccine Coverage: Inconsistent pneumococcal vaccine coverage globally results in uneven prevention outcomes. For instance, low vaccine uptake in Southeast Asia contributes to higher incidence rates.
Personalize this research.
Hotspot
Explore purchase options.
Table of Contents
| 1.       Introduction 1.1.    Research Methodology 1.2.    Scope of the Study 2.       Market Overview / Executive Summary 2.1.    Global Pneumonia Therapeutics Market (2018 – 2022) 2.2.    Global Pneumonia Therapeutics Market (2023 – 2029) 3.       Market Segmentation 3.1.    Global Pneumonia Therapeutics Market by Therapeutics 3.1.1. Prevention Vaccines 3.1.2. Treatment Drugs 3.2.    Global Pneumonia Therapeutics Market by Distribution Channel 3.2.1. Hospital 3.2.2. Pharmaceutical Stores 3.2.3. Others 3.3.    Global Pneumonia Therapeutics Market by Age Group 3.3.1. Paediatric 3.3.2. Adult 3.3.3. Geriatric 4.       Regional Segmentation 4.1.    North America 4.1.1. The US 4.1.2. Canada 4.1.3. Mexico 4.2.    South America 4.2.1. Brazil 4.2.2. Argentina 4.2.3. Colombia 4.2.4. Chile 4.2.5. Rest of South America 4.3.    Asia Pacific 4.3.1. China 4.3.2. India 4.3.3. Japan 4.3.4. South Korea 4.3.5. Rest of Asia Pacific 4.4.    Europe 4.4.1. The UK 4.4.2. Germany 4.4.3. Italy 4.4.4. France 4.4.5. Spain 4.4.6. Rest of Europe 4.5.    The Middle East 4.5.1. Turkey 4.5.2. UAE 4.5.3. Saudi Arabia 4.5.4. Rest of the Middle East 4.6.    Africa 4.6.1. Egypt 4.6.2. South Africa 4.6.3. Rest of Africa 5.       Value Chain Analysis of the Global Pneumonia Therapeutics Market 6.       Porter Five Forces Analysis 6.1.    Threats of New Entrants 6.2.    Threats of Substitutes 6.3.    Bargaining Power of Buyers 6.4.    Bargaining Power of Suppliers 6.5.    Competition in the Industry 7.       Trends, Drivers and Challenges Analysis 7.1.    Market Trends 7.1.1.    Market Trend 1 7.1.2.    Market Trend 2 7.1.3.    Market Trend 3 7.2.    Market Drivers 7.2.1.    Market Driver 1 7.2.2.    Market Driver 2 7.2.3.    Market Driver 3 7.3.    Market Challenges 7.3.1.    Market Challenge 1 7.3.2.    Market Challenge 2 7.3.3.    Market Challenge 3 8.       Opportunities Analysis 8.1.    Market Opportunity 1 8.2.    Market Opportunity 2 8.3.    Market Opportunity 3 9.       Competitive Landscape 9.1.    GSK Plc. 9.2.    Lupin Ltd. 9.3.    Bayer AG 9.4.    Teva Pharmaceutical Industries Ltd. 9.5.    Abbott Laboratories 9.6.    Company 6 9.7.    Company 7 9.8.    Company 8 9.9.    Company 9 9.10.  Company 10 |
Know the research methodology.
Pneumonia Therapeutics Market – FAQs
1. What is the current size of the pneumonia therapeutics market?
Ans. In 2024, the pneumonia therapeutics market size is USD 16,980.24 Mn.
2. Who are the major vendors in the pneumonia therapeutics market?
Ans. The major vendors in the pneumonia therapeutics market are GSK Plc.; Lupin Ltd.; Bayer AG; Teva Pharmaceutical Industries Ltd.; Abbott Laboratories.
3. Which segments are covered under the pneumonia therapeutics market segments analysis?
Ans. The pneumonia therapeutics market report offers in-depth insights into Therapeutics, Distribution Channel, Age Group, and Geography.